Hydroxyapatite is a naturally occurring mineral form of calcium apatite, with the chemical formula Ca10(PO4)6(OH)2. It is the major mineral component of human bones and teeth. Hydroxyapatite plays a key role in medical implants and allows for stronger anchoring of implants in bone tissue. It promotes bone growth and helps in faster recovery from fractures. The powder form of hydroxyapatite is widely used in oral care products, toothpaste, and dental cements, gels owing to its resemblance to the mineral content in dental enamel. It can repair small cavities and enhance enamel strength.

The Global Hydroxyapatite Market is estimated to be valued at US$ 2761.23 Mn in 2024 and is expected to exhibit a CAGR of 6.5% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Hydroxyapatite market are West Pharmaceutical Services Inc., Berry Global Inc., Sartorius AG, Corning Inc., Gerresheimer AG, SCHOTT AG, Stevanato Group, AptarGroup Inc., SGD Pharma, Ompi - Stevanato Group, DWK Life Sciences, Nipro Corporation, Nolato AB, Terumo Corporation, Qosina Corp.

The Hydroxyapatite Market Growth from medical implants applications is expected to drive market growth during the forecast period. Hydroxyapatite coatings on metallic implants enhance bioactivity and promote better osteoblast attachment, faster bone formation, and stronger bone–implant bonding.

Major players are expanding their Hydroxyapatite production capabilities in emerging markets of Asia Pacific, Latin America, and Middle East & Africa. This is attributed to increasing healthcare expenditure, rising prevalence of osteoporosis, and growth of medical devices industry in these regions.

Market Drivers

The increasing geriatric population globally is one of the major drivers of the Hydroxyapatite market. According to the United Nations, the number of people aged 60 years and above is expected to more than double, from 962 million globally in 2017 to 2.1 billion by 2050.With age, the risk of bone fractures increases considerably due to osteoporosis, arthritis or other bone-related diseases prevalent among the geriatric population. This is expected to drive the demand for Hydroxyapatite products for medical applications.